—New Hires Bring Extensive Industry Sales and Marketing Expertise—.
BALTIMORE, MD, April 8, 2015 – Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, today announced that it has hired two senior sales and marketing executives to support the rapid growth of its business. Melody Gretz has been named Vice President of Marketing and Market Access and Cindy Caccuro is the new Vice President of Enterprise Solution Sales.
Jeffrey Boschwitz, PhD, Chief Operating Officer at PGDx, commented “Our multiple product launches over the past six months, including our CancerSelectTM, PlasmaSelectTM–R and Enterprise Solution product lines, have generated a high level of interest from customers and increasingly robust growth. To better manage and accelerate our ongoing expansion, we have recruited these two accomplished sales and marketing executives to our team. Both Cindy and Melody bring a wealth of relevant expertise to PGDx, and we look forward to their contributions as we work together to advance the company to the next stage.”
Melody Gretz worked for the past decade at Quest Diagnostics, where she was promoted to positions of increasing responsibility. Most recently, she was Senior Director, Customer Retention for the South Region. Previously, Ms. Gretz was Director, Acquisitions & Enterprise Partnerships, where she as responsible for acquisitions and partnerships across the organization. Prior to that, Ms. Gretz spent five years as a leader on the Health Plan team, which was responsible for more than $3 billion in sales, where she developed and launched several revenue enhancing programs targeting payers. Earlier, she was Marketing Manager, then Director for Immunology, Asthma/Allergy, HIV/AIDS and Neurology. At Becton Dickinson (BD), Ms. Gretz began her career as Manager, Corporate Strategy & Business Development, before moving to Market Manager, Physician Office Lab. After launching BD’s Push Button Blood Collection Wing Sets, she was promoted to Global Brand Manager for Blood Collection Sets. Ms. Gretz received a BA degree from Washington and Lee University and an MBA from Columbia Business School.
Cindy Caccuro has a 15-year track record of achieving outstanding results in individual and team sales in the life sciences industry. Most recently, she was North East Regional Vice President at Miraca Life Sciences, where she directed a sales team specializing in pathology services. Her responsibilities included selling software, connectivity solutions and consultative services to major clients. Previously, Ms. Caccuro was Regional Manager at PLUS Diagnostics, where she directed a sales team covering multiple diagnostic product lines and molecular pathology testing. Earlier, she was a Senior Sales Business Development Executive at Dianon Systems, a LabCorp company focusing on pathology services. Ms. Caccuro began her career selling specialty pharmaceuticals for Novartis. She received a BA degree from Rutgers University.
PGDx’s CancerSelect Targeted Gene Panel analyzes FFPE samples to detect all major genetic alteration types with unmatched sensitivity and specificity, covering nearly all of the cancer genes currently associated with therapies that are FDA-approved or in actively-enrolling clinical trials. It also offers the option to compare tumor DNA with normal DNA to better differentiate cancer-specific mutations (somatic mutations) from mutations already present at birth (germline mutations.) PDGx’s PlasmaSelect–R analyzes samples from blood or plasma to detect sequence alterations and translocations in a panel of 63 well-characterized cancer genes. It is the first off-the-shelf plasma test that can analyze all major genetic alterations and detect mutations and translocations in circulating tumor DNA at levels as low as 0.1%. PGDx’s Enterprise Solution (ES) is a comprehensive turnkey solution that enables laboratories with NGS capability to run PGDx’s high quality cancer tests such as CancerSelect and PlasmaSelect in-house, while minimizing expense and effort.
PGDx is the only company offering a complete range of cancer genome analysis tools, including exome and targeted approaches for tissue specimens, targeted approaches for plasma samples and a variety of custom tissue and plasma-based options designed to address the specific research needs of cancer researchers and drug developers.
About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) provides advanced cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company uses advanced genomic methods and its deep expertise in cancer biology to identify and characterize the unique genomic alterations in tumors. PGDx’s proprietary methods for genome sequencing and analysis are complemented by its extensive experience in cancer genomics and clinical oncology. Co-founders Luis Diaz, MD, and Victor Velculescu, MD, PhD, are internationally recognized leaders in cancer genomics who have extensive experience in the practical application of advanced genomic technologies to research, drug development and clinical practice. PGDx’s CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians. For more information, visit www.personalgenome.com.
Help employers find you! Check out all the jobs and post your resume.
BALTIMORE, MD, April 8, 2015 – Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, today announced that it has hired two senior sales and marketing executives to support the rapid growth of its business. Melody Gretz has been named Vice President of Marketing and Market Access and Cindy Caccuro is the new Vice President of Enterprise Solution Sales.
Jeffrey Boschwitz, PhD, Chief Operating Officer at PGDx, commented “Our multiple product launches over the past six months, including our CancerSelectTM, PlasmaSelectTM–R and Enterprise Solution product lines, have generated a high level of interest from customers and increasingly robust growth. To better manage and accelerate our ongoing expansion, we have recruited these two accomplished sales and marketing executives to our team. Both Cindy and Melody bring a wealth of relevant expertise to PGDx, and we look forward to their contributions as we work together to advance the company to the next stage.”
Melody Gretz worked for the past decade at Quest Diagnostics, where she was promoted to positions of increasing responsibility. Most recently, she was Senior Director, Customer Retention for the South Region. Previously, Ms. Gretz was Director, Acquisitions & Enterprise Partnerships, where she as responsible for acquisitions and partnerships across the organization. Prior to that, Ms. Gretz spent five years as a leader on the Health Plan team, which was responsible for more than $3 billion in sales, where she developed and launched several revenue enhancing programs targeting payers. Earlier, she was Marketing Manager, then Director for Immunology, Asthma/Allergy, HIV/AIDS and Neurology. At Becton Dickinson (BD), Ms. Gretz began her career as Manager, Corporate Strategy & Business Development, before moving to Market Manager, Physician Office Lab. After launching BD’s Push Button Blood Collection Wing Sets, she was promoted to Global Brand Manager for Blood Collection Sets. Ms. Gretz received a BA degree from Washington and Lee University and an MBA from Columbia Business School.
Cindy Caccuro has a 15-year track record of achieving outstanding results in individual and team sales in the life sciences industry. Most recently, she was North East Regional Vice President at Miraca Life Sciences, where she directed a sales team specializing in pathology services. Her responsibilities included selling software, connectivity solutions and consultative services to major clients. Previously, Ms. Caccuro was Regional Manager at PLUS Diagnostics, where she directed a sales team covering multiple diagnostic product lines and molecular pathology testing. Earlier, she was a Senior Sales Business Development Executive at Dianon Systems, a LabCorp company focusing on pathology services. Ms. Caccuro began her career selling specialty pharmaceuticals for Novartis. She received a BA degree from Rutgers University.
PGDx’s CancerSelect Targeted Gene Panel analyzes FFPE samples to detect all major genetic alteration types with unmatched sensitivity and specificity, covering nearly all of the cancer genes currently associated with therapies that are FDA-approved or in actively-enrolling clinical trials. It also offers the option to compare tumor DNA with normal DNA to better differentiate cancer-specific mutations (somatic mutations) from mutations already present at birth (germline mutations.) PDGx’s PlasmaSelect–R analyzes samples from blood or plasma to detect sequence alterations and translocations in a panel of 63 well-characterized cancer genes. It is the first off-the-shelf plasma test that can analyze all major genetic alterations and detect mutations and translocations in circulating tumor DNA at levels as low as 0.1%. PGDx’s Enterprise Solution (ES) is a comprehensive turnkey solution that enables laboratories with NGS capability to run PGDx’s high quality cancer tests such as CancerSelect and PlasmaSelect in-house, while minimizing expense and effort.
PGDx is the only company offering a complete range of cancer genome analysis tools, including exome and targeted approaches for tissue specimens, targeted approaches for plasma samples and a variety of custom tissue and plasma-based options designed to address the specific research needs of cancer researchers and drug developers.
About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) provides advanced cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company uses advanced genomic methods and its deep expertise in cancer biology to identify and characterize the unique genomic alterations in tumors. PGDx’s proprietary methods for genome sequencing and analysis are complemented by its extensive experience in cancer genomics and clinical oncology. Co-founders Luis Diaz, MD, and Victor Velculescu, MD, PhD, are internationally recognized leaders in cancer genomics who have extensive experience in the practical application of advanced genomic technologies to research, drug development and clinical practice. PGDx’s CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians. For more information, visit www.personalgenome.com.
Help employers find you! Check out all the jobs and post your resume.
